Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential
Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as a year with some uncertainty.
Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as a year with some uncertainty.
While the big money made in utility stocks over the past five years is likely over, some of these top stocks still make good sense in a conservative growth and income portfolios.
The ups and downs of 2015 didn’t keep executives and 10% institutional owners from buying shares, and this past week, which marked the end of 2015, was no exception.
Baird has maintained Outperform ratings on three top companies that have reported outstanding numbers and had positive catalysts. All three could be solid additions to aggressive growth portfolios for 2016.
24/7 Wall St. screened the Merrill Lynch research database for stocks that performed well in 2014 but met with not only selling this year, but a degree of scorn from some of the analysts…
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
24/7 Wall St. screened the Merrill Lynch database for stocks that were rated Buy and that also did a significant amount of their sales and business overseas.
Oil won’t stay this low forever. In the meantime, it just makes sense for investors to stay with the large cap leaders that have survived these market downturns in the past.
While these stocks are only suitable for very aggressive risk tolerant accounts, the anticipated increase in spending in 2016 could make a solid difference to the top and bottom lines of these well-run companies.
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and growth next year.
While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities going forward.
One thing is for sure, the insiders and 10% owners did some late shopping and continued to buy stock this past week at a furious pace.
A new Deutsche Bank research report features three top bank picks for 2016 that provide very solid total return potential.
Coca-Cola shares are again a part of the UBS Dividend Ruler holdings, while British American Tobacco has been dropped.
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
Deutsche Bank has raised price targets on four premier airlines stocks, as the top airlines should do just fine in 2016.
With the potential for a year-end rally looking better after Monday's market action, many investors are turning their attention to end-of-the-year portfolio restructuring.
Should prices start to stabilize in the current trading area, these companies may provide investors some of the best entry points in the past 20 years.
24/7 Wall St. screened this week's top growth stocks picks at Jefferies and found four that could climb sharply if a end-of-year Santa Claus rally comes.
Oil won't stay this low forever. In the meantime, it just makes sense for investors to stay with the large cap leaders who have survived these market downturns in the past.